A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers.

Although endometrial thickness was reduced in volunteers receiving fulvestrant 125 mg compared with the placebo group, the mean difference was smaller and failed to reach statistical significance, suggesting the response to fulvestrant was dose related.

also in 6,035 other papers